About Charles Link
Charles Link is an executive chairman & chief innovation officer at Syncromune.
Charles Link reports to the SEC as a director, officer or major shareholder of 2 public companies: Telix Qsam (QSAM) and Lumos Pharma.
Charles Link first appears on SEC filings in 2011.
Experience
This experience comes from Charles Link's profile and from SEC filings. For roles taken from filings, the years are when the filings name Charles Link in the role, so the role may have started earlier or lasted longer.
Syncromune, Inc. Current
Executive Chairman & Chief Innovation Officer
Founder and Executive Chairman (2020 – Present)
2020 – Present · Fort Lauderdale, FL
Develops investigational immune therapies for people with metastatic solid tumors.
TI
Telix Qsam Inc.
Director
2022 – 2024 · Public company (QSAM)
VI
Viewpoint Molecular Targeting, Inc.
Board Member
2021 – 2024
QI
QSAM Biosciences, Inc.
Member Board Of Directors
2021 – 2024
LI
Lumos Pharma, Inc.
Chairman of the Board and CEO
2011 – 2019 · Public company
BC
BioProtection Systems Corporation
Founder, CEO
2010 – 2019
NG
NewLink Genetics
Founder, Chairman, CEO
1999 – 2019
Key Colleagues at Startups
The people Charles Link works with at each company, as listed on that company's latest Form D.
Syncromune, Inc. · Form D/A, May 11, 2026
JG
Joseph Gerardi
Executive officer
Jeffrey Cleland
Director
Douglas Watson
Lead Independent Director
JM
Joseph Maroon
Director
Stephen Dale
Chief Medical Officer
NS
Norman Schwartz
Director
Eamonn Hobbs
President & Chief Executive Officer, director
Kerri-Ann Millar
Chief Financial Officer
Agustin Gago
Chief Operating Officer